{"name":"Athenex","slug":"athenex","ticker":"ATNX","exchange":"NASDAQ","domain":"athenex.com","description":"Athenex is a biopharmaceutical company focused on oncology and specialty therapeutics. The company's top drugs include Orascovery (oral paclitaxel) and KX2-391. Athenex has a strong presence in the US market and is expanding globally.","hq":"Buffalo, NY","founded":0,"employees":"","ceo":"Johnson Lau","sector":"Specialty Pharma / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$52M","metrics":{"revenue":101229000,"revenueGrowth":13.6,"grossMargin":0,"rdSpend":51758000,"netIncome":-103427000,"cash":204055000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Orascovery patent cliff ($1.2B at risk)","drug":"Orascovery","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Oradoxel","genericName":"Oradoxel","slug":"oradoxel","indication":"Other","status":"phase_1"},{"name":"Oratecan","genericName":"Oratecan","slug":"oratecan","indication":"Other","status":"phase_1"},{"name":"Oratopo","genericName":"Oratopo","slug":"oratopo","indication":"Other","status":"phase_1"},{"name":"Oraxol","genericName":"Oraxol","slug":"oraxol","indication":"Other","status":"discontinued"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"IV paclitaxel","genericName":"IV paclitaxel","slug":"iv-paclitaxel","indication":"Metastatic breast cancer","status":"phase_3"}]}],"pipeline":[{"name":"IV paclitaxel","genericName":"IV paclitaxel","slug":"iv-paclitaxel","phase":"phase_3","mechanism":"IV paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Ovarian cancer","Kaposi sarcoma"],"catalyst":""},{"name":"Oradoxel","genericName":"Oradoxel","slug":"oradoxel","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oratecan","genericName":"Oratecan","slug":"oratecan","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oratopo","genericName":"Oratopo","slug":"oratopo","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oraxol","genericName":"Oraxol","slug":"oraxol","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Athenex Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Athenex reported net sales of $142.8 million for the fourth quarter and $533.3 million for the full year 2023.","drugName":"","sentiment":"neutral"},{"date":"2023-11-16","type":"deal","headline":"Athenex Announces Exclusive Distribution Agreement with Hikma Pharmaceuticals for Orascovery in the US","summary":"Athenex partnered with Hikma Pharmaceuticals to distribute Orascovery in the US.","drugName":"","sentiment":"positive"},{"date":"2023-09-29","type":"regulatory","headline":"Athenex Receives FDA Approval for Orascovery (oral paclitaxel) in Combination with Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer","summary":"The FDA approved Orascovery in combination with bevacizumab for first-line treatment of metastatic colorectal cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2023-10-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-08-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQZ1psTjh1M21KOEpUNzlaZU16SXNyTDNvUWJvb3MzeHI3WUNTd3JnMlYtTlcyaGxYS2NtcGJTcXF6VDZhZ2dfZVZ4UUhhZXN5YkdBR3pyMEVEbGhWc1ZKVzFNTi1SdlRTSVp1ZWVYLWNnUV82ZzFON2ZsOXN5Uy14dXducUtUWWF2WXFtZlNQN0V6VWRvcWgxZTRTc3h0QXIwZG9ZSm1rZ25KOWVMQjNDYnZ2OU9HaXRvRERLQWFFOHBJbURac3J5ZmdGVTZGcUVxRTNodmpzUTJ1VkJPTHdyZHA5bUc?oc=5","date":"2023-07-31","type":"pipeline","source":"WGRZ","summary":"Athenex assets sold in bankruptcy auction; top executives dismissed - WGRZ","headline":"Athenex assets sold in bankruptcy auction; top executives dismissed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQYjVGY2ZlUHZkcy1qajNITmJURjZMMGFja1lXa3hfWjlvSnhZd1Zmb1c0RHE3STVlMmx2R1VjMHZra19pLVZGeE5CdjVFamp6bzRMWlVTdE9odi1uVzRaaXBvQ2tsMndfUDZNdUxKNUhuN1RENUdJTXBKcDZMUm0tdGJFZ3VyZEFSckJRc3ctTmlRRndmTWc?oc=5","date":"2023-07-31","type":"pipeline","source":"The Business Journals","summary":"Athenex assets sold in bankruptcy auction; top executives dismissed - The Business Journals","headline":"Athenex assets sold in bankruptcy auction; top executives dismissed","sentiment":"neutral"},{"date":"2023-07-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-05-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPT3FNSHUtMm40cEo0ZWxEY0tsU3BVc0dqRVJtaW5kdjVZTk83TXBZWnZlSkRqZEY1U0RVcVAzMkRMV0xtelpYc3BvYWtFNXY1UUtZMWlQcFVFUGtub2dGMVlUejU0Y0Vvb0pKR1BESHJRZXotaldpbHRweGo3cVlsVThmTlBQTUxlbzZ5TDVYckdWVVpqV3dOSll4SUxIQlN6bVdSR3VzQWJYRmZabGRxWFVuYS01TzdK?oc=5","date":"2023-05-15","type":"deal","source":"Fierce Biotech","summary":"Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit - Fierce Biotech","headline":"Athenex files for bankruptcy, seeks buyer for natural killer T-cell therapy unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPRTFodnlpSnZ5cG5xY2FVeEFReFpmMnFjWnFQM2tmUEdkdWZWcUNuUUdGRXpuWDVJSWdQWVpZeTJWZ0JLcGQ0cnJ3R1dZM3lIalB5MWJSTk01LW84b3NQNGRiOWpRcFFieGlwcVgzaDlyM3hqWUlPSlhWU0hfdmhxajY1eHAxQU1EcFE?oc=5","date":"2023-05-15","type":"pipeline","source":"Yahoo Finance","summary":"Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge - Yahoo Finance","headline":"Athenex Voluntarily Filed For Chapter 11 Proceedings, Shares Plunge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQZkZicnZwWUtLRDJoQXY5Q1E0YkV6ZGFZc25FcVg4MUp4Uml0YUZfdVoxVTk1dGlHOVkxdU9LVXlZSWwwS19jQlR0VC1LV3FtV3VzMEtDbk1zRXQ3UTVDdy1wZnZ4bnRTTjdyWngybE9iZjdsWVNHc0tJS2NVaXBtVlRndWJEaUUxV0tJ?oc=5","date":"2023-05-14","type":"pipeline","source":"Yahoo Finance","summary":"Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process - Yahoo Finance","headline":"Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQT0ZCanN0blE4dFZLTll5UFlSdGk4MTVwV2hMbWdxeHNEVS1YOFV4aEUtM3Y3LWJlMkNOUzl0Vnl2YjJXZWFFZ2lDeGJRLTI0cW14R3VPYlBxN2VyOS1MR25mR0xmQ19GdzluT2FQd2Z4b3pQVk5jbElfU2NDNF9hSmdKWmprWWJCNl9aYzVrckZlYUFuV2VEdng0dWpLLXdDaU85azJaNGxlVFk?oc=5","date":"2023-05-10","type":"pipeline","source":"The Business Journals","summary":"Pine Pharmaceuticals assumes part of Athenex’s business and 50 workers - The Business Journals","headline":"Pine Pharmaceuticals assumes part of Athenex’s business and 50 workers","sentiment":"neutral"},{"date":"2023-05-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-04-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPTXNWbG1scThDcEx6RldFamdMNVJydzZqX2RKZHluMTlUMWRpdjNZakdic2c3emVzcnRGVTN3SjNSYUZVbm5XUHZMSkZvZkxqaFRCZFZONWpwX0ZDQzVwbFYtSHliZjJ5dFRHR09yd2JVNm5DZXBMQjVmSkRpUFZCV0lGYzVkYUtTV1N1OU93?oc=5","date":"2022-03-03","type":"pipeline","source":"The Business Journals","summary":"ImmunityBio enters Western New York ready to build upon Athenex success - The Business Journals","headline":"ImmunityBio enters Western New York ready to build upon Athenex success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPcnJLRnUtbjZxbHEtWThfbS0yQTZlaHVudUhKNFY2ckVSelBtdVVEdlVsNnlROHRVeHpOZGRvNnlPaUVfeVhYc1luRW1MZ3RGVkQ3NFhfLTFGVXRBX3V6bjdhUnlDNHFEcDlZR2UwWFA2a3lhQnZwTlpKYng5cVo5aVd6bFh6RTVYX2toUg?oc=5","date":"2022-01-13","type":"deal","source":"The Business Journals","summary":"Inside the Athenex-ImmunityBio deal — and the California company's employment plans - The Business Journals","headline":"Inside the Athenex-ImmunityBio deal — and the California company's employment plans","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQUXNZLWpEQWR4UWFsUlJCMm5xd3E0VFZyZmU4dHlyNFZZYXJaemhvZnE4aExQTHgzb3RieG5JWDE0MGM4RW5NUTNORm9kYW5PVVYwblRiN2NvTGVpSEVaVEdXOXNZTjh6UDRTRDhJS05mRE1fT3pPVmswZ0swamlpSWNoeHY0eExDNlBPLUNQTGxJNXMzZXNxbWtJX1pBMHFLUTZn?oc=5","date":"2020-12-02","type":"pipeline","source":"Yahoo Finance","summary":"Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide - Yahoo Finance","headline":"Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosph","sentiment":"neutral"}],"patents":[{"drugName":"Orascovery","drugSlug":"oral-paclitaxel","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":5,"phaseCounts":{"phase_3":1,"phase_1":3,"discontinued":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Merck & Co.","Bristol-Myers Squibb"],"therapeuticFocus":["Oncology","Specialty Therapeutics"],"financials":{"source":"sec_edgar+yahoo","revenue":101229000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":101229000,"period":"2019-12-31"},{"value":89100000,"period":"2018-12-31"},{"value":89100000,"period":"2018-12-31"},{"value":38043000,"period":"2017-12-31"},{"value":38043000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":51758000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-103427000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":204055000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}